NCKU-Department of Pharmacology

Welcome to NCKU-Department of Pharmacology

Cheung, Chun Hei Antonio

 N A M E / T I T L E
 ( Cheung, Chun Hei Antonio, Ph.D., MRSNZ )
 T E L
 886-6 235-3535 ext 5503
 F A X
 886-6 274-9296
 E - M A I L

  Ph.D, Molecular Medicine, The University of Auckland, New Zealand
  B.Tech with First Class Honours, Biomedical science, The University of Auckland,  New Zealand

Tamoxifen is a hormone modulator that has been widely used as an anti-cancer agent. Typically, patients with estrogen receptor positive (ER-positive) breast tumors will receive Tamoxifen either as a first line treatment or as a second line treatment after surgery. Despite the benefit of using Tamoxifen as hormonal therapy in treating ER-positive breast cancers has been widely demonstrated in patients at early treatment stages, its effectiveness seems to be significantly reduced in patients after five years post-treatment. Interestingly, two thirds of the tumors that become resistant to Tamoxifen continue to express ER. Thus, it is necessary to develop novel strategies that can be applied to target both ER-positive Tamoxifen-resistant and estrogen-independent breast cancer cells


Investigations on the possibility of using Survivin inhibitors for the treatment of Tamoxifen-resistant or estrogen-independent breast cancers


2011 - NHRI Research Day “Elected paper” award

2010 - American Association for Cancer Research Scholar-in-training award finalist

2010 - The 15 th Taiwan Joint Cancer Conference “Outstanding research poster” award

2010 - NHRI Research Day “Excellent research poster” award

2009 - NHRI Research Day “Elected thesis” award

2009 - The University of Auckland International Doctoral Scholar

2006 - The Maurice & Phyllis Paykel Trust Post-graduate travel award
KL Chen, WS Chang, CHA Cheung , CC Lin, CC Huang, YN Yang, CP Kuo, CC Kuo, YH Chang, KJ Liu, CM Wu and JY Chang * ; Targeting cathepsin S induces tumor cell autophagy via the EGFR-ERK signaling pathway; Cancer Lett. (SCI, in press)

HP Hsieh, CHA Cheung , WH Lin, TA Hsu, MS Coumar, YS Chao and JY Chang; BPR1K653, a novel aurora kinase inhibitor, exhibits potent anti-proliferative activity in P-gp170 (MDR1)-mediated VX680-resistant cancer cells in vitro and in vivo; EJC Suppl. (2011) 47(1):S127-S127 (SCI)

JR Kanwar * , RK Kanwar, G Mahidhara and CHA Cheung ; Cancer targeted nanoparticles specifically induce apoptosis in cancer cells and spare normal cells; Australian Journal of Chemistry (SCI, in press)
JR Kanwar, X Sun, CHA Cheung * ; ML-IAP (Livin) and human cancers: A recent review (invited review); WebmedCentral CANCER (2011) 2(9):WMC002159
CHA Cheung , WH Lin, TA Hsu, TC Hour, TK Yeh, S Ko, TW Lien, MS Coumar, CF Liu, WY Lai, HY Shiao, TR Lee, HP Hsieh and JY Chang * ; BPR1K653, a novel pan-Aurora kinase inhibitor that exhibits potent anti-proliferative activity in multi-drug resistant cancer cells ; PLoS ONE (2011) 6(8): e23485 (SCI)
YN Yang, KM Chou, WY Pan, YW Chen, TC Tsou, S Yeh, CHA Cheung , LT Chen and JY Chang * ; Enhancement of non-homologous end joining DNA repair capacity confers cancer cells resistance to the novel selenophene compound, D-501036; Cancer Lett. (2011) 309(1):110-118 (SCI)
CHA Cheung # , MS Coumar # , JY Chang and HP Hsieh * ; Aurora kinase inhibitor patents and agents in clinical testing: An update (2009-10) (invited review); Expert Opin. Ther. Patents (2011) 21(6):857-884 (SCI) .
CHA Cheung , LT Cheng, KY Chang, HH Chen and JY Chang * ; Investigations of survivin: the past, present and future (invited review); Front. Biosci. (2011) 16:952-961 (SCI)
L Ma, H Qiao, Q Yang, C He, X Jiang, CHA Cheung , JR Kanwar and X Sun * ; Modulating the interaction of CXCR4 and SDF-1α by low-molecular-weight heparin inhibits hepatic metastasis of colon cancer; Invest. New Drugs (2010) Nov 16 [Epub ahead of print] (SCI)
CHA Cheung , SY Wu, TR Lee, CY Chang, JS Wu, HP Hsieh and JY Chang * ; Cancer cells acquire mitotic drug resistance properties through beta I-tubulin mutations and alterations in the expression of beta-tubulin isoptypes; PLoS ONE (2010) 5(9):e12564 (SCI)
CHA Cheung , HH Chen, LT Cheng, KW Lyu, JR Kanwar and JY Chang * ; Targeting Hsp90 with small molecule inhibitors induces the over-expression of the anti-apoptotic molecule, survivin, in human A549, HONE-1 and HT-29 cancer cells; Mol. Cancer (2010) 9:77 (SCI)
JR Kanwar * , RK Kanwar and CHA Cheung ; Oral nanodelivery of small interfering RNA and micro RNA gene therapy in for breast and colon cancers; FFHD Suppl. (2010) 1: 221-222
S Baratchi, RK Kanwar, CHA Cheung and JR Kanwar * ; Proliferative and protective effects of SurR9-C84A on differentiated neural cells; J. Neuroimmunol. (2010) 227(1-2):120-132 (SCI)
CHA Cheung , X Sun, JR Kanwar, JZ Bai, LT Cheng and GW Krissansen * ; A cell-permeable dominant-negative protein targeting survivin induces apoptosis and sensitizes prostate cancer cells to TNF-alpha therapy; Cancer Cell Int. (2010) 10:36 (SCI)

•  RK Kanwar, CHA Cheung , JY Chang and JR Kanwar * ; Recent advances in anti-survivin treatments for cancer (review); Curr. Med. Chem. (2010) 17(15):1509-1515 (SCI)

CC Hsieh, YH Kuo, CC Kuo, LT Chen, CHA Cheung , TY Chao, CH Lin, WY Pan, CY Chang, SC Chien, TW Chen, CC Lung and JY Chang * ; Chamacypanone C, a novel skeleton microtubule inhibitor, with anticancer activity by trigger caspase 8-Fas/FasL dependent apoptotic pathway in human cancer cells; Biochem. Pharmacol. (2010) 79(9):1261-1271 (SCI) .
CHA Cheung , MS Coumar, HP Hsieh and JY Chang * ; Aurora kinase inhibitors in preclinical and clinical testing (review); Expert Opin. Investig. Drugs (2009) 18(4):379-398 (SCI)
MS Coumar, CHA Cheung , JY Chang and HP Hsieh * ; Advances in aurora kinase inhibitor patents (review); Expert Opin. Ther. Patents (2009) 19(3):321-356 (SCI)
CHA Cheung , HH Chen, CC Kuo, CY Chang, MS Coumar, HP Hsieh and JY Chang * ; Survivin counteracts the therapeutic effect of microtubule de-stabilizers by stabilizing tubulin polymers; Mol. Cancer (2009) 8:43 (SCI)
Click Num  
  • Forward to friend
  • Print
  • Add to my favorie .
  • Share
Forward to friend
Please input CAPTCHA